Durlobactam

Summary

Durlobactam (CHEMBL4298137) is an approved small-molecule EC 3.5.2.6 (β-lactamase) inhibitor; indicated across 1 condition including bacterial infectious disease.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• Indications: 1 condition
• Clinical trials: 1
• Chemistry: 277.26 Da · C8H11N3O6S

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL4298137
Name	Durlobactam
Type	Small molecule
Max phase	4
FDA approved	yes
PubChem CID	89851852
ChEBI	CHEBI:229539
Molecular formula	C8H11N3O6S
Molecular weight	277.26
InChIKey	BISPBXFUKNXOQY-RITPCOANSA-N

SMILES: CC1=C[C@@H]2CN([C@@H]1C(=O)N)C(=O)N2OS(=O)(=O)O

IUPAC name: [(2S,5R)-2-carbamoyl-3-methyl-7-oxo-1,6-diazabicyclo[3.2.1]oct-3-en-6-yl] hydrogen sulfate

ChEBI definition: A member of the class of azabicycloalkanes that is (1R,2S,5R)-3-methyl-7-oxo-1,6-diazabicyclo[3.2.1]oct-3-ene-2-carboxamide in which the amino hydrogen at position 6 is replaced by a sulfooxy group.

Pharmacological roles (ChEBI): EC 3.5.2.6 (β-lactamase) inhibitor, antibacterial drug.

Also known as: Durlobactam, EXT2514, DURLOBACTAM

Parent form; salt/anhydrous children: CHEMBL4297378

Patent coverage: 45 distinct patent families (124 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 108 (87%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 indication (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
bacterial infectious disease	1	MONDO:0005113	EFO:0000771

Clinical trials

Total trials: 1.

Phase distribution

Phase	Trials
PHASE3	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT03894046	PHASE3	COMPLETED	Study to Evaluate the Efficacy and Safety of Intravenous Sulbactam-ETX2514 in the Treatment of Patients With Infections Caused by Acinetobacter Baumannii-calcoaceticus Complex

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).